These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3017406)

  • 1. Importance of the 10-13 region of glucagon for its receptor interactions and activation of adenylate cyclase.
    Krstenansky JL; Trivedi D; Hruby VJ
    Biochemistry; 1986 Jul; 25(13):3833-9. PubMed ID: 3017406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
    McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
    Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoiodoglucagon: synthesis, purification by high pressure liquid chromatography, and characteristics as a receptor probe.
    Rojas FJ; Swartz TL; Iyengar R; Garber AJ; Birnbaumer L
    Endocrinology; 1983 Aug; 113(2):711-9. PubMed ID: 6307649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of specific trinitrophenylation of the lysine epsilon amino group of glucagon on receptor binding and adenylate cyclase activation.
    Liepnieks JJ; Epand RM
    Arch Biochem Biophys; 1983 Aug; 225(1):102-9. PubMed ID: 6311099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for glucagon receptor binding and activation of adenylate cyclase in liver. Study of chemically modified forms of the hormone, including N alpha-trinitrophenyl glucagon, an antagonist.
    Epand RM; Rosselin G; Hoa DH; Cote TE; Laburthe M
    J Biol Chem; 1981 Feb; 256(3):1128-32. PubMed ID: 6256384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of glucagon partial agonists and antagonists.
    Gysin B; Trivedi D; Johnson DG; Hruby VJ
    Biochemistry; 1986 Dec; 25(25):8278-84. PubMed ID: 3814583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential acid stabilities of citraconylated amino groups of glucagon. Preparation of N alpha-citraconyl glucagon and evaluation of its biological properties.
    Liepnieks JJ; Epand RM
    Biochim Biophys Acta; 1982 Oct; 707(2):171-7. PubMed ID: 6291617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-function relationships in glucagon. Re-evaluation of glucagon-(1-21).
    Frandsen EK; Thim L; Moody AJ; Markussen J
    J Biol Chem; 1985 Jun; 260(12):7581-4. PubMed ID: 2987259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
    Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
    J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The glucagon receptor from liver can be functionally fused to caudate nucleus adenylate cyclase.
    Tolkovsky AM; Martin BR
    FEBS Lett; 1982 Dec; 150(2):337-42. PubMed ID: 6297980
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of nonspecific hydrophobic interactions in the biological activity of N epsilon-acyl derivatives of glucagon. Studies of conformation, receptor binding, and adenylate cyclase activation.
    Carrey EA; Epand RM
    J Biol Chem; 1982 Sep; 257(18):10624-30. PubMed ID: 6286664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of the C-terminal alpha-helical structure for glucagon's biological activity.
    Krstenansky JL; Zechel C; Trivedi D; Hruby VJ
    Int J Pept Protein Res; 1988 Dec; 32(6):468-75. PubMed ID: 2854536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon: structure-function relationships investigated by sequence deletions.
    Frandsen EK; Grønvald FC; Heding LG; Johansen NL; Lundt BF; Moody AJ; Markussen J; Vølund A
    Hoppe Seylers Z Physiol Chem; 1981 Jun; 362(6):665-77. PubMed ID: 6268519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase.
    Hoosein NM; Gurd RS
    FEBS Lett; 1984 Dec; 178(1):83-6. PubMed ID: 6094259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of 2-thioltryptophan-glucagon and (tryptophan-S-glucagon)2. Differences in binding to the glucagon receptor in the hepatic adenylate cyclase system.
    Wright DE; Rodbell M
    J Biol Chem; 1980 Nov; 255(22):10884-7. PubMed ID: 7430160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of amidinated glucagons.
    Wright DE; Rodbell M
    Eur J Biochem; 1980 Oct; 111(1):11-6. PubMed ID: 7439177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New glucagon analogues with conformational restrictions and altered amphiphilicity: effects on binding, adenylate cyclase and glycogenolytic activities.
    Hruby VJ; Gysin B; Trivedi D; Johnson DG
    Life Sci; 1993; 52(10):845-55. PubMed ID: 8445980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-stimulable adenylyl cyclase in rat liver. The impact of streptozotocin-induced diabetes mellitus.
    Dighe RR; Rojas FJ; Birnbaumer L; Garber AJ
    J Clin Invest; 1984 Apr; 73(4):1013-23. PubMed ID: 6323532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.